![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: MAGEB10 |
Gene summary for MAGEB10 |
![]() |
Gene information | Species | Human | Gene symbol | MAGEB10 | Gene ID | 139422 |
Gene name | MAGE family member B10 | |
Gene Alias | MAGEB10 | |
Cytomap | Xp21.3 | |
Gene Type | protein-coding | GO ID | GO:0000122 | UniProtAcc | Q96LZ2 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
139422 | MAGEB10 | HCC1 | Human | Liver | HCC | 7.19e-14 | 9.30e-01 | 0.5336 |
139422 | MAGEB10 | HCC2 | Human | Liver | HCC | 1.12e-12 | 6.89e-01 | 0.5341 |
139422 | MAGEB10 | HCC5 | Human | Liver | HCC | 1.75e-08 | 8.45e-01 | 0.4932 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | CRC | ![]() |
Stomach | GC | ![]() |
Stomach | CAG with IM | ![]() |
Stomach | CSG | ![]() |
Stomach | CAG | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MAGEB10 | SNV | Missense_Mutation | rs756349026 | c.991N>C | p.Thr331Pro | p.T331P | Q96LZ2 | protein_coding | tolerated(0.33) | benign(0.029) | TCGA-A8-A096-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
MAGEB10 | SNV | Missense_Mutation | c.7N>G | p.Arg3Gly | p.R3G | Q96LZ2 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-A8-A09G-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
MAGEB10 | SNV | Missense_Mutation | c.805N>T | p.Pro269Ser | p.P269S | Q96LZ2 | protein_coding | deleterious(0.02) | possibly_damaging(0.824) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
MAGEB10 | SNV | Missense_Mutation | novel | c.660G>T | p.Glu220Asp | p.E220D | Q96LZ2 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
MAGEB10 | SNV | Missense_Mutation | c.113C>T | p.Ser38Phe | p.S38F | Q96LZ2 | protein_coding | tolerated(0.61) | benign(0.01) | TCGA-E2-A159-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD | |
MAGEB10 | SNV | Missense_Mutation | novel | c.706N>G | p.Ile236Val | p.I236V | Q96LZ2 | protein_coding | deleterious(0.04) | benign(0.03) | TCGA-LL-A5YO-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
MAGEB10 | SNV | Missense_Mutation | c.875T>G | p.Leu292Trp | p.L292W | Q96LZ2 | protein_coding | tolerated(0.09) | benign(0.249) | TCGA-C5-A1MJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
MAGEB10 | SNV | Missense_Mutation | novel | c.312T>A | p.Asp104Glu | p.D104E | Q96LZ2 | protein_coding | tolerated(1) | benign(0.001) | TCGA-C5-A902-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
MAGEB10 | SNV | Missense_Mutation | c.271N>A | p.Glu91Lys | p.E91K | Q96LZ2 | protein_coding | tolerated(0.1) | benign(0.406) | TCGA-DG-A2KH-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
MAGEB10 | SNV | Missense_Mutation | novel | c.58G>C | p.Gly20Arg | p.G20R | Q96LZ2 | protein_coding | tolerated(0.22) | possibly_damaging(0.558) | TCGA-HM-A3JJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |